Ieq Capital LLC Grows Stock Position in Bruker Co. (NASDAQ:BRKR)

Ieq Capital LLC lifted its stake in Bruker Co. (NASDAQ:BRKR) by 961.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 58,950 shares of the medical research company’s stock after buying an additional 53,394 shares during the period. Ieq Capital LLC’s holdings in Bruker were worth $3,456,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Alberta Investment Management Corp purchased a new position in shares of Bruker in the fourth quarter worth about $598,000. Global Retirement Partners LLC increased its holdings in shares of Bruker by 16.5% in the fourth quarter. Global Retirement Partners LLC now owns 5,135 shares of the medical research company’s stock worth $301,000 after buying an additional 726 shares during the period. New York State Common Retirement Fund increased its holdings in shares of Bruker by 11.2% in the fourth quarter. New York State Common Retirement Fund now owns 247,355 shares of the medical research company’s stock worth $14,500,000 after buying an additional 24,916 shares during the period. Kestra Investment Management LLC increased its holdings in shares of Bruker by 54.0% in the fourth quarter. Kestra Investment Management LLC now owns 13,855 shares of the medical research company’s stock worth $812,000 after buying an additional 4,859 shares during the period. Finally, Kornitzer Capital Management Inc. KS increased its holdings in shares of Bruker by 74.7% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 145,000 shares of the medical research company’s stock worth $8,500,000 after buying an additional 62,000 shares during the period. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Stock Down 4.0 %

BRKR stock opened at $50.82 on Friday. Bruker Co. has a fifty-two week low of $48.07 and a fifty-two week high of $94.86. The business’s 50 day moving average price is $56.73 and its two-hundred day moving average price is $60.03. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The company has a market capitalization of $7.70 billion, a price-to-earnings ratio of 66.87, a price-to-earnings-growth ratio of 2.16 and a beta of 1.16.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. As a group, analysts forecast that Bruker Co. will post 2.69 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BRKR. Citigroup reduced their price target on Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Stifel Nicolaus reduced their price target on Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a report on Friday, February 14th. The Goldman Sachs Group upgraded Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price target on the stock in a report on Thursday, December 5th. UBS Group began coverage on Bruker in a report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 price target on the stock. Finally, Wells Fargo & Company reduced their price target on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Bruker has an average rating of “Moderate Buy” and a consensus price target of $70.50.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.